GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Alimera Sciences Inc (ALIM) [hlAlert]

Rating:
Outperform
ALIM
down 64.48 %

Alimera Sciences Inc (ALIM) rated Outperform with price target $14 by Oppenheimer

Posted on: Monday,  Dec 27, 2010  8:25 AM ET by Oppenheimer

Oppenheimer rated Outperform Alimera Sciences Inc (NASDAQ: ALIM) on 12/27/2010. Previously Oppenheimer rated Outperform Alimera Sciences Inc (NASDAQ: ALIM) on 06/02/2010.,
when the stock price was $9.49. Since then, Alimera Sciences Inc has lost 64.49% as of 08/27/2015's recent price of $3.37.
If you would have followed the previous Oppenheimer's recommendation on ALIM, you would have lost 64.48% of your investment in 1912 days.

Alimera Sciences, Inc. is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien, which the Company is developing for the treatment of diabetic macular edema (DME). The Company has completed enrollment of 956 patients in two Phase 3 pivotal clinical trials for the use of Iluvien in the treatment of DME across the United States, Canada, Europe and India. Iluvien is an intravitreal insert designed to provide a sustained therapeutic effect for up to 36 months by delivering a low daily dose of fluocinolone acetonide (FA), a corticosteroid with demonstrated efficacy in the treatment of ocular diseases. Iluvien is inserted into the patient?s eye with a 25-gauge needle, which allows for a self-sealing wound.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/27/2010 8:25 AM Buy
None
9.54 14.00
as of 12/31/2010
1 Week down  -19.78 %
1 Month down  -21.32 %
3 Months down  -5.95 %
1 YTD down  -13.29 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/2/2010 8:25 AM Buy
None
9.49 16.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy